Pharma and Biotech Industry Outlook - A look at trends and opportunities

• Report rights infringement
• published: 11 Jun 2015
• views: 316

1. Pharma and Biotech Industry Outlook A gander at patterns and opportunities in this undeniably difficult environment with an emphasis on the generics landscapeOctober 2012rbhuller@frost.com 2. Market Overview 2 3. Dreary Industry Growth Despite R&D; Investment• The enormous worldwide marked pharma and biotech industry will create $1,092.0 billion in income by 2015.• Despite critical R&D; interest in key territories like oncology, respiratory operators, lipid controllers, antidiabetescompounds, and antipsychotics the business is conveying just single digit top-line development. Source: Frost & Sullivan 9837 Changing Dynamics in the Pharma and Biotech Industry, June 2012. 3 4. Non specific Pharmaceuticals Market SummaryHow huge is the business sector and how quick What are current business progress and what are the outer challenges?is it developing? District: Global Generic medication incomes embody more or less 15 percent of the world pharmaceutical market and are growing 2-3 times quicker than the pharmaceutical business. United States, Germany, France, Revenue Growth ($ Billion) Rate (%) Japan, the United Kingdom, Canada, Italy, and Spain; represent 80.0 percent of the aggregate bland medication deals around the world. The developing markets, Brazil, Russia, India, China, and Turkey are2012 154.14 - anticipated that would grow 15-20 percent when contrasted with the development rates of full grown generics markets at2013 168.84 9.5 just 6-10 percent. Key restorative zones for generics infiltration incorporate cardiovascular disease,2014 183.70 8.8 oncology, rheumatology, and sicknesses of the focal sensory system. Generics cost 20-90 percent not exactly marked pharmaceuticals in this way decreasing social insurance costs. Contrasting administrative and2015 198.99 7.9 repayment forms all inclusive keep on representing a test to generics manufacturers.What are the key opportunities and dangers for this business? Which organizations are effective in this business sector and why? Opportunities Risks Company (Market Share) • Broad product offerings that span• A $150 billion business sector will be • Market solidification of generics Teva (18.0%) different sickness ranges open to generics rivalry producers through collusions, • Strategic acquisitions mergers, and acquisitions just Sandoz (10.0%) from patent expiry of blockbuster • Regulatory support from EMA, medications like Lipitor (Pfizer) and reinforce the predominant players. Mylan (6.0%) EDQM, FDA Zyprexa (Eli Lilly). • Branded pharmaceutical Watson (3.0%) organizations have created • Products are high quality• India and China are the biggest Stada Arzeimittal counter methods to counteract • Diversified portfolio incorporates market opportunities at $10.0 (2.0%) piece of the overall industry disintegration like claim to fame restorative territories billion and $26.5 billion adding to their own generics Other* (61.0%) • Efficient worldwide appropriation channels individually. inside. *Other incorporates incomes of remaining business sector members. Source: Frost & Sullivan M74E Generic Pharmaceuticals Market- A Global Analysis, December 2011. 4 5. Biosimilars Market SummaryHow enormous is the business sector and how quick What are current business progress and what are the outside challenges?is it developing? District: Global The Biologics Price Competition and Innovation Act of 2009 (BPCIA) secured a curtailed administrative pathway for the endorsement of biosimilars, will make ready into an undiscovered U.S. market Revenue Growth ($ Billion) Rate (%) which speaks to just 15 percent of the worldwide business sector. The great European administrative environment has permitted various biosimilar regards prompting 40 percent of the global2012 1,034.2 - market. The staying worldwide piece of the overall industry is driven by India and China biosimilar markets. Clinical2013 1,701.3 64.5 trial prerequisites for biosimilars are more thorough than those for routine generics and include to2014 2,798.7 64.5 advancement expenses and last evaluating. Potential incredulity to biosimilars may be overcome with unprejudiced instructive projects for doctors that pass on persuading non-inadequacy clinical data2015 4,603.8 64.5 for items from respectable organizations exceedingly experienced with biologics.What are the key opportunities and dangers for this business sector? Which organizations are fruitful in this business and why? Opportunities Risks Company (Global Market • Cost Share in 2010)• Patent expiries of blockbuster • Products with distinctive • Safety and viability information biologics display huge business organization courses may pick up Sandoz International